The ADD1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population in which the ADD1 gene is disrupted to ablate alpha-adducin expression. This heterogeneous pool of HT29-derived cells offers a versatile loss-of-function model without clonal selection, enabling robust analysis of ADD1-dependent phenotypes in a colorectal adenocarcinoma background. The CRISPR/Cas9-mediated gene disruption provides a reliable platform for studying adducin??s roles in epithelial cell biology.
The parental HT29 cell line originates from a human colorectal adenocarcinoma and retains key characteristics of intestinal epithelial cells, including barrier formation, proliferation, and differentiation. It expresses tight junction components and exhibits regulated ion transport, making it an ideal host for examining cytoskeletal adapter proteins. HT29??s well-established signaling pathways and compatibility with diverse assays enhance the utility of gene-edited derivatives for cancer and epithelial research.
Alpha-adducin, encoded by ADD1, crosslinks spectrin to actin filaments, stabilizing the cortical cytoskeleton at cell junctions and membrane domains. It is phosphorylated by PKC and PKA downstream of calcium/calmodulin and RhoA signaling, modulating its affinity for spectrin and actin and thereby regulating membrane stability, cell shape, and migration. Adducin forms complexes with ADD2 and ADD3, and interacts with calmodulin, protein phosphatase 2A, Na+/K+ ATPase, and tight junction proteins occludin and ZO-1 to control ion transport and barrier integrity. The RhoA?CROCK?CLIMK?Ccofilin pathway further links adducin to actin remodeling and myosin light chain phosphorylation.
Disruption of ADD1 in HT29 cells provides a focused model to investigate alpha-adducin??s contributions to intestinal epithelial barrier function and ion transport. Because HT29 cells form tight junctions, the knockout system is especially suited for examining adducin-dependent regulation of paracellular permeability and electrolyte flux. Loss of adducin may alter cell adhesion, migration, and proliferation, processes relevant to colorectal cancer progression. Moreover, the association of ADD1 with salt-sensitive hypertension enables studies of epithelial sodium transport in a cancer context, bridging cytoskeletal dynamics and disease mechanisms.
This polyclonal knockout pool is amenable to western blotting, immunofluorescence, and co-immunoprecipitation for confirming adducin loss and probing cytoskeletal complexes. Cell migration assays and barrier integrity measurements assess functional roles in motility and tight junction maintenance. Phospho-signaling analysis, RT-qPCR, and flow cytometry further support mechanistic and expression profiling, while drug sensitivity studies allow evaluation of therapeutic vulnerabilities. For additional information, please contact Ascent Research.
